A small proportion of chronic myeloid leukemia patients treated with interferon-α (IFN-α) monotherapy are able to discontinue the treatment without disease relapse although residual leukemia cells are present. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.